No Data
No Data
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Innovative drug concept rises against the market, with Innovent Bio (01801) increasing by 3.85%. The State Drug Administration has agreed to carry out related evaluation and approval pilots in Beijing and Shanghai.
Jingu Wealth News | Innovative drug concept rises against the trend, with Remegen (09995) up 6.15%, Innovent Bio (01801) up 3.85%, Akeso (09926) up 2.84%, Hutchmed (China) (00013) up 2.55%, Frontage (01521) up 2.41%, Innocare (09969) up 1.96%, Canbridge Life Sciences-B (02162) up 1.86%, and BeiGene (06160) up 1.21%. The National Medical Products Administration has approved the pilot program for optimizing clinical trial evaluation and approval of innovative drugs in Beijing and Shanghai after review.
Hong Kong stock concept tracking | National Medical Products Administration approved the pilot program of optimizing the clinical trial review and approval of innovative drugs in Peking and Shanghai, and innovative drugs are expected to outperform other s
The pharmaceutical industry is expected to see overall year-on-year improvement and quarter-on-quarter growth in performance in the second half of the year.
Hong Kong stock concept tracking | Diabetes prevention and control action plan released, significant progress has been made in the innovative drug research and development of these enterprises (with concept stocks).
According to Frost & Sullivan data, the scale of China's diabetes medication market is expected to reach 167.5 billion yuan by 2030.
Trending Industry Today: FRONTAGE Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
No Data